Payment overview · 2025
General Payments
$267.22
14 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan P Binder, MD
Allopathic & Osteopathic Physicians|Family Medicine · CASPER, WY · NPI 1841214954
Verified facts
What the public records show
CMS Open Payments records show Jonathan P Binder, MD received $267.22 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.22 | 20.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.41 | 18.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.07 | 18.0% | 3 | 2025 |
| Digestive Care, Inc. | Unresolved — no canonical attribution shown | $36.80 | 13.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.43 | 11.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $27.96 | 10.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.33 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.22 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.22 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.07 | 3 | 2025 |
Source payment records
|
|||||
| Pertzye Normalized: pertzye |
Drug | Digestive Care, Inc. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.96 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 96 |
| Gabapentin | Gabapentin | 330 | 64 |
| Lisinopril | Lisinopril | 311 | 80 |
| Omeprazole | Omeprazole | 290 | 70 |
| Metformin Hcl | Metformin Hcl | 249 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 60 |
| Simvastatin | Simvastatin | 226 | 54 |
| Losartan Potassium | Losartan Potassium | 201 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 35 |
| Allopurinol | Allopurinol | 146 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 29 |
| Tramadol Hcl | Tramadol Hcl | 142 | 30 |
| Trazodone Hcl | Trazodone Hcl | 142 | 33 |
| Potassium Chloride | Potassium Chloride | 140 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 25 |
| Sertraline Hcl | Sertraline Hcl | 111 | 29 |
| Eliquis | Apixaban | 104 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 27 |
| Alendronate Sodium | Alendronate Sodium | 101 | 26 |
| Furosemide | Furosemide | 97 | 31 |
| Finasteride | Finasteride | 95 | 27 |
| Ozempic | Semaglutide | 95 | 14 |
| Glipizide | Glipizide | 88 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 18 |
| Lorazepam | Lorazepam | 86 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 20 |
| Glimepiride | Glimepiride | 77 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 15 |
| Famotidine | Famotidine | 71 | 16 |
| Atenolol | Atenolol | 69 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 13 |
| Ezetimibe | Ezetimibe | 67 | 14 |
| Meloxicam | Meloxicam | 66 | 18 |
| Warfarin Sodium | Warfarin Sodium | 63 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 13 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Olanzapine | Olanzapine | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 16 |
| Chlorthalidone | Chlorthalidone | 52 | 11 |
| Baclofen | Baclofen | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Prednisone | Prednisone | 45 | 28 |
| Synthroid | Levothyroxine Sodium | 45 | 11 |
| Carvedilol | Carvedilol | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Azithromycin | Azithromycin | 32 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Risperidone | Risperidone | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.22 · 14 records | GlaxoSmithKline, LLC. | BREZTRI, LILETTA, NURTEC ODT, Pertzye, QULIPTA, REXULTI, TRELEGY ELLIPTA, YUPELRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error